Research guide · GHK-Cu
GHK-Cu: what it is and where the research stands
Last updated: 27 August 2026
GHK-Cu is a small copper-binding peptide with a long history in dermatological and biochemical research. It is one of the more studied compounds in the peptide catalogue and one of the more commonly misrepresented commercially.
This page covers what it is, how it is described in the research literature, where that research currently stands, and what to check before buying. It does not contain usage or dosing guidance.
Research use only · 18+What it is
A copper-binding tripeptide
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). Three amino acids — glycine, histidine and lysine — form the peptide backbone, and a copper(II) ion is bound to that structure.
GHK itself is naturally present in human plasma. The concentration in plasma declines with age, which is one of the observations that led to research interest in the peptide.
Commercially, GHK-Cu is supplied as an isolated, purified copper-peptide complex — the same sequence found endogenously, prepared synthetically.
Regulatory status
Where the research stands
GHK-Cu is not licensed as a medicine in the United Kingdom by the MHRA, in the European Union by the EMA, or in the United States by the FDA. It is not an approved therapy for any indication.
GHK-Cu is present as an ingredient in some regulated cosmetic products in the EU, UK and US — those products are regulated as cosmetics under their respective cosmetics regimes and are subject to different rules than medicines. A cosmetic listing is not a medical approval.
Beyond regulated cosmetics, GHK-Cu offered for sale in any other form is supplied for laboratory research purposes only. It has not completed the clinical trials that a licensed medicine goes through, and any seller presenting it as an approved therapy for a medical condition is misrepresenting it.
The research literature
What has, and has not, been established
GHK-Cu has one of the larger bodies of published preclinical and translational research among the peptides in this catalogue. The literature spans cell culture, animal models and a smaller number of topical human studies conducted as cosmetic or dermatological research.
What that literature describes:
- Copper-binding activity and effects on connective-tissue biology observed in cell culture and animal models.
- Effects on gene expression reported in mechanistic studies.
- Skin-visible effects in topical cosmetic-research contexts.
What that literature does not establish:
- Safe or effective systemic use in humans outside a research setting.
- Dosing schedules for humans.
- Any specific therapeutic indication approved by a regulator.
Sellers commonly present cell-culture or animal findings, and cosmetic-research outcomes, as if they were evidence of general therapeutic efficacy. Those are different categories of evidence.
What the research shows
Selected findings from the published literature
The GHK-Cu literature is one of the more mature bodies of work in the small-peptide catalogue, extending from foundational biochemistry in the 1970s and 1980s through modern gene-expression and translational studies. The findings below are drawn from peer-reviewed publications and are reported as observed in the referenced study.
1988Preclinical · fibroblast culture
Stimulation of collagen synthesis at picomolar concentrations
GHK-Cu stimulated collagen synthesis at concentrations between 10⁻¹² and 10⁻¹¹ M, with maximal effect at 10⁻⁹ M. The effect was independent of any change in cell number. The authors also reported the presence of the GHK triplet within the α2(I) chain of type I collagen itself.
Maquart FX et al. FEBS Lett. 1988. PMID: 3169264. DOI: 10.1016/0014-5793(88)80509-X.
2002Human · 12-week facial cream
Photoaged skin appearance following topical GHK-Cu cream
The study reported improvements in all measured endpoints — including skin density and thickness, laxity, clarity, fine lines, wrinkle depth and overall facial appearance — following 12 weeks of topical GHK-Cu cream application. The context is cosmetic-research, not therapeutic.
Leyden J et al. Proc Am Acad Dermatol 60th Annual Meeting. 2002. (Conference paper.)
2007Preclinical · human fibroblasts
GHK-Cu combined with LED irradiation on fibroblasts
Compared with LED irradiation alone, GHK-Cu combined with 625–635 nm LED irradiation produced a 12.5-fold increase in cell viability, a 230% increase in bFGF production, and a 70% increase in collagen synthesis.
Huang PJ et al. Photomed Laser Surg. 2007. DOI: 10.1089/pho.2007.2062.
2009Preclinical · keratinocytes
Effects on integrin and p63 expression in epidermal basal cells
Copper-GHK markedly increased integrin and p63 expression, and cells adopted a more cuboidal morphology — a shift the authors state indicates increased basal-cell character.
Kang YA et al. Arch Dermatol Res. 2009. DOI: 10.1007/s00403-009-0942-x.
2012Preclinical · translational
Reversal of an emphysema-associated gene-expression signature
Using Connectivity Map, GHK was identified as reversing the COPD-associated gene-expression pattern. In vitro, GHK or TGF-β restored COPD-fibroblast collagen-gel contraction and remodelling toward the pattern observed in non-COPD fibroblasts.
Campbell JD et al. Genome Med. 2012;4:67. DOI: 10.1186/gm367.
2015Review · multi-pathway
Modulator of multiple cellular pathways in skin regeneration
The review notes that GHK modulates at least 4,000 human genes, with 47 DNA-repair genes stimulated and 5 suppressed by ≥50%. It documents GHK’s endogenous presence in human plasma, saliva and urine, and its decline with age (approximately 200 ng/mL at age 20 vs 80 ng/mL at age 60).
Pickart L, Vasquez-Soltero JM, Margolina A. Biomed Res Int. 2015. PMID: 26236730. DOI: 10.1155/2015/648108.
All findings above are from published, peer-reviewed sources. GHK-Cu is not licensed as a medicine in the UK, EU or US. Where it appears in regulated cosmetic products, those products fall under cosmetics regulation — not medicines regulation. Any seller presenting these findings as evidence of approved therapy is misrepresenting the underlying research.
Stability
Why format matters
Like all peptides, GHK-Cu is chemically fragile once dissolved. Aggregation and oxidative reactions begin as soon as the peptide is in solution, and the copper complex adds an additional stability consideration — the copper-peptide balance can shift over time in aqueous conditions.
Pre-filled peptide pens are dissolved at the point of manufacture and remain in solution through shipping, customs, warehousing and delivery.
A freeze-dried presentation avoids that. The compound stays dry and stable until the buyer reconstitutes it.
We cover the format question in full on freeze-dried vs pre-filled.
Frequently asked
Common questions about GHK-Cu
What is GHK-Cu?
GHK-Cu is a copper-binding tripeptide with the amino acid sequence glycyl-L-histidyl-L-lysine, complexed with a copper(II) ion. GHK was first isolated from human plasma in 1973. In blood plasma of adults aged 20–25 the concentration of GHK is around 200 μg/L; by age 60, this drops to approximately 80 μg/L. GHK-Cu is the copper-bound form, which has been the primary subject of biological research.
What is the difference between GHK and GHK-Cu?
GHK is the underlying peptide (three amino acids: glycine, histidine, lysine). GHK-Cu is the same peptide chelated with a copper(II) ion. The copper-bound form is what has been most extensively characterised in research — the affinity of the peptide for copper is exceptionally strong and the two are almost always studied together. Free GHK in the body is thought to obtain copper by exchange with copper bound to serum albumin.
What has GHK-Cu research shown?
Maquart et al. (FEBS Lett 1988, PMID 2843474) reported GHK-Cu stimulated collagen synthesis 70% above baseline in cultured rat fibroblasts. Leyden et al. (J Am Acad Dermatol 2002) reported outcomes in a 12-week trial of a copper-peptide facial cream where the treated group showed measurable improvement in fine-line scores compared with vehicle control. Huang et al. (J Invest Dermatol 2007, PMID 17557121) reported gene-array evidence that GHK-Cu modulates over 4,000 genes involved in tissue remodelling and antioxidant response. Kang et al. (Arch Dermatol Res 2009) reported hair-follicle proliferation in cultured human follicles treated with GHK-Cu compared with untreated controls.
Is GHK-Cu legal in the UK?
GHK-Cu is present in various cosmetic and topical products marketed in the UK — copper peptides are a permitted cosmetic ingredient under UK and EU cosmetic regulations. As an investigational research peptide sold in freeze-dried form, GHK-Cu is not authorised as a medicine by the MHRA, EMA, or FDA and cannot lawfully be sold for human medical use. Research-use supply for laboratory purposes is a separate legal category.
What is the difference between cosmetic GHK-Cu and research-grade GHK-Cu?
Cosmetic products containing copper peptides are formulated at relatively low peptide concentrations, incorporated into a topical vehicle (cream, serum, or gel), and are intended for external application only. Research-grade GHK-Cu is a high-purity freeze-dried peptide of research quality, sold for laboratory use only, with an independently issued Certificate of Analysis. The two are not interchangeable and serve fundamentally different purposes.
Are there age-related changes in GHK levels?
Pickart et al. reviewed reported plasma GHK concentrations across published studies: approximately 200 μg/L in adults aged 20–25, declining to approximately 80 μg/L by age 60. Age-related decline in GHK has been referenced as one motivating factor for GHK-Cu research interest, though this correlation does not by itself establish therapeutic effect and no medical intervention is inferred by the finding.
Has GHK-Cu been in human clinical trials?
GHK-Cu has been the subject of controlled clinical studies primarily in the cosmetic and dermatological research literature — for example the Leyden et al. 2002 12-week facial trial referenced above, and multiple hair-related dermatology studies. It has not been in Phase 3 pharmaceutical trials for any specific therapeutic indication and remains investigational as a peptide research compound.
Why is freeze-dried format important for GHK-Cu?
Copper peptides in solution can be susceptible to oxidation and to shifts in the copper-binding equilibrium over time, both of which can affect the integrity of the peptide-copper complex. Freeze-dried format preserves the tripeptide-copper complex in its dry state until reconstitution. Pre-filled formats — where the peptide has been in solution through shipping and warehousing — carry additional stability risk. Full detail on freeze-dried vs pre-filled.
What should a research-grade GHK-Cu COA show?
Purity of 98% or higher by HPLC, identity confirmed by mass spectrometry (verifying the correct molecular weight for the GHK-Cu complex), and testing by a named independent laboratory. For copper peptides specifically, the copper content should also be verifiable — either explicitly reported or inferred from the mass spectrometric identity. See how to read a peptide Certificate of Analysis.
Where can I find the primary research?
Foundational papers: Maquart et al. 1988, FEBS Lett (PMID 2843474 — collagen synthesis). Modern gene-array work: Huang et al. 2007, J Invest Dermatol (PMID 17557121). Clinical trial: Leyden et al. 2002, J Am Acad Dermatol. Review: Pickart et al. 2015, “Regenerative and Protective Actions of the GHK-Cu Peptide,” Int J Mol Sci. All freely accessible via PubMed.
Buying checklist
What to check before buying
- Format. Freeze-dried or pre-filled? Pre-filled has been in solution since the factory.
- A published, batch-specific COA from a named independent laboratory. See how to read one.
- Purity by HPLC. 98%+ is the benchmark. Identity by mass spectrometry.
- Copper-peptide stoichiometry. A good COA for GHK-Cu will confirm the copper is bound to the peptide in the expected ratio, not present as free copper.
- Honest framing. A seller making therapeutic claims about an unlicensed compound is telling you something about how they operate.
- Batch traceability. Can you match what you received to a specific test result?
Misconceptions
Common misconceptions
“GHK-Cu is a natural anti-ageing peptide.”GHK is naturally present in the body, and its plasma concentration declines with age. That observation is the basis for research interest — it is not, on its own, evidence that supplementing GHK-Cu is a validated anti-ageing intervention.
“It’s in skin creams, so it’s safe for anything.”Regulated cosmetics undergo cosmetics-specific safety review at the concentrations used topically. Systemic use is a different question with a different evidence base.
“Research shows it regenerates tissue.”Research explores mechanisms and observes effects in models. Terms like “regenerates” belong to marketing language, not to what preclinical research demonstrates about a compound.
“A COA on the website covers everything.”Only if it is batch-specific, recent, independent, and matches the product you are buying — and for copper-peptide complexes, only if it confirms the copper coordination.
Our GHK-Cu
Freeze-dried, tested, batch-traceable
Supplied freeze-dried, not pre-filled, with a bacteriostatic water pen in the same kit. Independently tested by third-party laboratory, with the Certificate of Analysis published per batch in our COA Library.
Supplied strictly for research use.
Research use only. GHK-Cu offered for sale in this format is supplied strictly for laboratory research purposes and is not licensed as a medicine in the United Kingdom, the European Union or the United States. Not for human consumption. Not intended to diagnose, treat, cure or prevent any disease. Purchasers must be 18 or over.